Domain adaptation may be a novel creative solution to predict infection risk in patients with chronic lymphocytic leukemia ...

The Alliance for Clinical Trials in Oncology has launched a new clinical trial for adults who need first-line therapy for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The ...

The combination of AstraZeneca's Calquence and AbbVie/Roche's Venclexta has become the first all-oral, fixed-duration regimen for patients with newly-diagnosed chronic lymphocytic leukaemia (CLL) in ...

Panelists discuss challenges oncologists face in managing treatment-naive patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), including balancing efficacy with adverse ...

Researchers assessed whether venetoclax-obinutuzumab would be safe and effective in fit and unfit patients with previously untreated CLL.

After nearly a decade of treatment, a Texas woman reached remission through an FDA-approved cellular therapy for chronic lymphocytic leukemia.

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, ...

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the combination regimen of VENCLEXTA® (venetoclax) and ...

AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with venetoclax has been approved in the US as the first all-oral, fixed-duration regimen for the treatment of adult patients with chronic ...

AbbVie announces US FDA approves combination treatment of Venclexta and acalabrutinib for previously untreated patients with CLL: North Chicago, Illinois Monday, February 23, 2026 ...

The approval was based on the AMPLIFY trial, which evaluated acalabrutinib alongside venetoclax in adults with previously untreated CLL without del(17p) or TP53 mutation.

Chronic Lymphocytic Leukaemia Advocates NZ (CLL Advocates NZ) welcomes the announcement by Pharmac that the combination therapies of Ibrutinib + Venetoclax and Obinutuzumab + Venetoclax will be funded ...